Protection from primary infection and establishment of latency by vaccination with a herpes simplex virus type 1 recombinant deficient in the virion host shutoff (vhs) function

Vaccine

Volumn 16, Issue 1, 1998, Pages 1-5

  Walker, Joy ^a   Leib, David A ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

HSV; Latency; Vaccine

Indexed keywords

HERPES VACCINE; LIVE VACCINE; NEUTRALIZING ANTIBODY; RECOMBINANT VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DELETION MUTANT; FEMALE; HERPES; HERPES SIMPLEX VIRUS 1; MOUSE; NONHUMAN; PRIMARY INFECTION; PRIORITY JOURNAL; VACCINATION; VIRUS RECOMBINANT; VIRUS REPLICATION;

ANIMALS; ANTIBODIES, VIRAL; FEMALE; HERPES SIMPLEX; IMMUNOGLOBULIN G; MICE; SIMPLEXVIRUS; VACCINES, ATTENUATED; VACCINES, SYNTHETIC; VIRAL PROTEINS; VIRAL VACCINES;

EID: 0031986439     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(97)00164-3     Document Type: Article

References (26)

1. Banks T.A., Nair S., Rouse B.T. Recognition by and in vitro induction of cytotoxic T lymphocytes against predicted epitopes of the immediate-early protein ICP27 of herpes simplex virus. Journal of Virology. 67:1993;613-616.
2. Becker Y., Tavor E., Asher Y., Berkowitz C., Moyal M. Effect of herpes simplex virus type-1 UL41 gene on the stability of mRNA from the cellular genes: β-actin, fibronectin, glucose transporter-1, and docking protein, and on virus intraperitoneal pathogenicity to newborn mice. Virus Genes. 7:1993;133-143.
3. Berthommé H., Jacquemont B., Epstein A. The pseudorabies virus host-shutoff homolog gene: nucleotide sequence and comparison with alphaherpesvirus protein counterparts. Virology. 193:1993;1028-1032.
4. Boursnell M.E., Entwisle C., Blakeley D., Roberts C., Duncan I.A., Chisholm S.E., Martin G.M., Jennings R., Ni Challanain D., Sobek I., Inglis S.C., McLean C.S. A genetically inactivated herpes simplex virus type 2 (HSV-2) vaccine provides effective protection against primary and recurrent HSV-2 disease. Journal of Infectious Diseases. 175:1997;16-25.
5. Burke R.L. Development of a herpes simplex virus subunit glycoprotein vaccine for prophylactic and therapeutic use. Reviews of Infectious Diseases. 199:1991;906-911.
6. Davido, D.J. and Leib, D.A., Role of cis-acting sequences of the ICP0 promoter of herpes simplex virus type 1 in viral pathogenesis, latency and reactivation. Journal of General Virology, 77 1853-1863.
7. Davidson H.J., Byrnes S.A., Montgomery P.C. The effect of immunization route on rat serum and tear antibody responses to Chlamydia trachomatis. Regional Immunology. 5:1993;114-119.
8. DeLuca N.A., McCarthy A.M., Schaffer P.A. Isolation and characterization of deletion mutants of herpes simplex virus type 1 in the gene encoding immediate-early regulatory protein ICP4. Journal of Virology. 56:1985;558-570.
9. DeLuca N.A., Schaffer P.A. Activities of herpes simplex virus type 1 (HSV-1) ICP4 genes specifying nonsense peptides. Nucleic Acids Research. 15:1987;4491-4511.
10. Dixon R.A.F., Schaffer P.A. Fine-structure mapping and functional analysis of temperature-sensitive mutants in the gene encoding the herpes simplex virus type 1 immediate early protein VP175. Journal of Virology. 36:1980;189-203.
11. Dundarov S., Andonov P., Balakov B., Nechev K., Tomov C. Immunotherapy with inactivated polyvalent herpes vaccines. Developments in Biological Standardization. 52:1982;351-358.
12. Katz J.P., Bodin E.T., Coen D.M. Quantitative polymerase chain reaction analysis of herpes simplex virus DNA in ganglia of mice infected with replication-incompetent mutants. Journal of Virology. 64:1990;4288-4295.
13. Kwong A.D., Frenkel N. Herpes simplex virus-infected cells contain a function(s) that destabilizes both host and viral mRNAs. Proceedings of the National Academy of Sciences of the United States of America. 84:1987;1926-1930.
14. Morrison L.A., Knipe D.M. Immunization with replication-defective mutants of herpes simplex virus type 1: Sites of immune intervention in pathogenesis of challenge virus infection. Journal of Virology. 68:1994;689-696.
15. Nesburn A.B., Burke R.L., Ghiasi H., Slanina S., Bahri S., Wechsler S.L. Vaccine therapy for ocular herpes simplex virus (HSV) infection: Periocular vaccination reduces spontaneous ocular HSV type shedding in latently infected rabbits. Journal of Virology. 68:1994;5084-5092.
16. Osterrieder N., Wagner R., Brandmuller C., Schmidt P., Wolf H., Kaaden O.R. Protection against EHV-1 challenge infection in the murine model after vaccination with various formulations of recombinant glycoprotein gp14 (gB). Virology. 208:1995;500-510.
17. Rader K.A., Ackland-Berglund C.E., Miller J.K., Pepose J.S., Leib D.A. In vivo characterization of site-directed mutations in the promoter of the herpes simplex virus type 1 latency-associated transcripts. Journal of General Virology. 74:1993;1859-1869.
18. Simmons A., Nash A.A. Role of antibody in primary and recurrent herpes simplex virus infection. Journal of Virology. 53:1985;944-948.
19. Skinner G.R., Fink C., Melling J., Wiblin C., Thornton B., Hallworth J., Gardner W., McLeish P., Hartley C., Buchan A. Report of twelve years experience in open study of Skinner herpes simplex vaccine towards prevention of herpes genitalis. Medical Microbiology and Immunology. 180:1992;305-320.
20. Straus S.E., Corey L., Burke R., Savarese B., Barnum G., Krause P.R., Khost R.G., Meier J. L, Sekulovich R., Adair S.F., Dekker C.L. Placebo-controlled trial of vaccination with recombinant glycoprotein D of herpes simplex virus type 2 for immunotherapy of genital herpes. Lancet. 343:1994;1460-1463.
21. Strelow L.I., Leib D.A. Role of the virion host shutoff (vhs) of herpes simplex virus type 1 in latency and pathogenesis. Journal of Virology. 69:1995;6779-6786.
22. Strelow L.I., Leib D.A. Analysis of conserved domains of UL41 of herpes simplex virus type 1 in virion host shutoff and pathogenesis. Journal of Virology. 70:1996;5665-5667.
23. Thompson P., Wells P.A., Sandstrom I.K., Opremcak E.M., Millin J.A., Daigle J., Foster C.S. Immunomodulation of experimental herpes simplex keratitis 1. UV-HSV protection. Current Eye Research. 7:1988;1043-1049.
24. + CTL clones recognize HSV-2-infected fibroblasts after treatment with IFN-gamma or when virion host shutoff functions are disabled. Journal of Immunology. 156:1996;3901-3910.
25. Watson R., Clements J.B. A herpes simplex virus type 1 function continuously required for early and late virus RNA synthesis. Nature. 285:1980;329-330.
26. Wildy, P., Field, H.J. and Nash, A.A., Classical herpes latency revisited. In Virus Persistence, ed. B.W.J. Mahy, A.C. Minson and G.K. Darby, Cambridge University Press, Cambridge, UK, 1982, pp. 133-167.